Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
28 hedge funds and large institutions have $550K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
2% less capital invested
Capital invested by funds: $562K → $550K (-$11.9K)
7% less funds holding
Funds holding: 30 → 28 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$9.72K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$237 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exos Asset Management
New York
|
-$18.1K |
| 2 |
CS
Clear Street
New York
|
-$653 |
| 3 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$554 |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$40 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
26
Bulldog Investors
Saddle Brook,
New Jersey
| $1.61K | -$554 | -4,180 | -21% |
|
|
WC
27
Wealthspring Capital
West Harrison,
New York
| $1.34K | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $10 | – | – | – |
|
|
EAM
29
Exos Asset Management
New York
| – | -$18.1K | -178,900 | Closed |
|
|
30
UBS Group
Zurich,
Switzerland
| – | -$2 | -22 | Closed |
|
BLACR Hedge Fund Activity: Q3 2024 in Review
28 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q3 2024, worth a combined $550K — down 2.1% from $562K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BLACR and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was Cowen and Company, adding an estimated $9.72K. The largest seller was Exos Asset Management, exiting entirely with an estimated $18.1K sold.
- 28 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q3 2024, down from 30 in Q2 2024.
- Funds reported $550K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q3 2024, down 2.1% quarter-over-quarter.
- 1 fund opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q3 2024 was Cowen and Company, an estimated $9.72K added.
- The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q3 2024 was Exos Asset Management, an estimated $18.1K sold.
Based on aggregated 13F filings for Q3 2024.